Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Apr;35(4):783–784. doi: 10.1128/aac.35.4.783

Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.

J A Bosso 1, B A Saxon 1, J M Matsen 1
PMCID: PMC245101  PMID: 1906264

Abstract

The comparative in vitro activity and synergy of cefepime were evaluated with clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. The activity of cefepime, both alone and in combination, was comparable to those of other antibiotics. The clinical efficacy of cefepime in cystic fibrosis patients merits investigation.

Full text

PDF
783

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bosso J. A., Black P. G. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis J. 1988 Mar;7(3):171–176. doi: 10.1097/00006454-198803000-00008. [DOI] [PubMed] [Google Scholar]
  2. Fuchs P. C., Jones R. N., Barry A. L., Thornsberry C. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1985 May;27(5):679–682. doi: 10.1128/aac.27.5.679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fung-Tomc J., Dougherty T. J., DeOrio F. J., Simich-Jacobson V., Kessler R. E. Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels. Antimicrob Agents Chemother. 1989 Apr;33(4):498–502. doi: 10.1128/aac.33.4.498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fung-Tomc J., Huczko E., Pearce M., Kessler R. E. Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime. Antimicrob Agents Chemother. 1988 Sep;32(9):1443–1445. doi: 10.1128/aac.32.9.1443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gold R., Overmeyer A., Knie B., Fleming P. C., Levison H. Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatr Infect Dis. 1985 Mar-Apr;4(2):172–177. doi: 10.1097/00006454-198503000-00012. [DOI] [PubMed] [Google Scholar]
  6. Kessler R. E., Bies M., Buck R. E., Chisholm D. R., Pursiano T. A., Tsai Y. H., Misiek M., Price K. E., Leitner F. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics. Antimicrob Agents Chemother. 1985 Feb;27(2):207–216. doi: 10.1128/aac.27.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Khan N. J., Bihl J. A., Schell R. F., LeFrock J. L., Weber S. J. Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins. Antimicrob Agents Chemother. 1984 Oct;26(4):585–590. doi: 10.1128/aac.26.4.585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Padoan R., Brienza A., Crossignani R. M., Lodi G., Giunta A., Assael B. M., Granata F., Passarella E., Vallaperta P. A., Xerri L. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis. J Pediatr. 1983 Aug;103(2):320–324. doi: 10.1016/s0022-3476(83)80377-1. [DOI] [PubMed] [Google Scholar]
  9. Schaad U. B., Wedgwood-Krucko J., Guenin K., Buehlmann U., Kraemer R. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):858–865. doi: 10.1007/BF01963771. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES